SEATTLE (March 29, 2026) Newly published, peer-reviewed results of observational clinical research have demonstrated that ID Genomics’ “bacterial fingerprinting” technology has the potential to improve antibiotic prescribing, reducing prescription errors and the overuse of broad-spectrum [...]
ID Genomics will present its pitch in MedTech Innovators’ lightning round on March 15th. Thanks to Wings and Life Sciences Washington for the opportunity! MedTech Innovator [...]
ID Genomics will present a booth advertising its genomics’ Services at Alliance Northwest (http://alliancenorthwest.org). We have been proudly offering Services such as 16S rRNA typing, MultiLocus Sequence Typing, antibiotic susceptibility testing, and Staphylococcus aureus SPA typing to [...]
IDG will present its work at the 13th Annual NIH CAP FeedForward(TM) Sessions. We thank the LARTA Institute for this opportunity and welcome mentor feedback! http://www.larta.org [...]
The Company’s novel approach in matching the infecting bug with the correct drug the first time has been covered by Modern Healthcare: Innovations. Please read the entire text [...]
ID Genomics, Inc. has launched a first of its kind initiative that brings together clinical partners in an effort to combat antibiotic resistance worldwide. Covered by GenomeWeb, please read more about our efforts [...]
SEATTLE (January 11, 2026) ID Genomics, Inc. announced the formation of a national consortium of clinical partners to help increase the rapidity and accuracy of infectious disease diagnosis and antibiotic treatment through the company’s novel DNA-based “bacterial fingerprinting” diagnostics [...]
ID Genomics’ CEO, Dr. Kaveri Parker, will present the Company’s technology and its implications for the American warfighter at the Defense Innovation Challenge in Austin, TX. Please come visit our showcase exhibit at booth 313W in Griffin Hall at the JW Marriott. [...]
As the recipient of a $3 million, 3-year Phase II SBIR grant, ID Genomics has been selected for the Commercialization Acceleration Program sponsored by the National Institutes of Health and the Larta Institute. The goal of this program is to assist early stage companies in commercializing their [...]
ID Genomics, Inc. has been selected as an Innovation Challenge company by the Redefining Early Stage Investments (RESI) Conference in Boston, MA. Please come visit our poster and learn more about the conference here: [...]